UPLOAD Filing
CDT Equity Inc.
Date: Aug. 5, 2025 · CIK: 0001896212 · Accession: 0000000000-25-008236
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289125
Letter
Re: Conduit Pharmaceuticals Inc. Registration Statement on Form S-3 Filed July 31, 2025 File No. 333-289125 Dear Andrew Regan:
August 5, 2025
Andrew Regan Chief Executive Officer Conduit Pharmaceuticals Inc. 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Todd Mason, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 5, 2025 Andrew Regan Chief Executive Officer Conduit Pharmaceuticals Inc. 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103 Re: Conduit Pharmaceuticals Inc. Registration Statement on Form S-3 Filed July 31, 2025 File No. 333-289125 Dear Andrew Regan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Todd Mason, Esq. </TEXT> </DOCUMENT>